Corticosteroid-use in primary and secondary brain tumour patients: A review

Journal of Neuro-Oncology

Volumn 106, Issue 3, 2012, Pages 449-459

  Ryan, Richella ^a   Booth, Sara ^a,b,c   Price, Stephen ^a,b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Brain neoplasms; Corticosteroids; Quality of life

Indexed keywords

ARACHIDONIC ACID; BEVACIZUMAB; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; FLUDROCORTISONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN TUMOR; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; CUSHINGOID SYNDROME; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG USE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; HYPERGLYCEMIA; INSOMNIA; LIFE EXPECTANCY; MENTAL DISEASE; METASTASIS; MYOPATHY; NEUROMODULATION; PEPTIC ULCER; PRESCRIPTION; PRIMARY TUMOR; PROTEIN EXPRESSION; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; TIGHT JUNCTION; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; HUMANS;

EID: 84857047133     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0713-3     Document Type: Review

References (69)

1. Galicich JH, French LA, Melby JC (1961) Use of dexamethasone in treatment of cerebral edema associated with brain tumors. Lancet 81:46-53
2. Galicich JH, French LA (1961) Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am Pract Dig Treat 12:169-174
3. Weissman DE, Dufer D, Vogel V, Abeloff MD (1987) Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 5:125-128 (Pubitemid 17125234)
4. McClelland S, 3rd, Long DM (2008) Genesis of the use of corticosteroids in the treatment and prevention of brain edema. Neurosurgery 62:965-967 discussion 967-968
5. Prados M, Strowger B, Feindel WH (1945) Studies on cerebral edema: reaction of the brain to air exposure; pathologic changes. Arch Neurol Psychiatry 54:163-174
6. Ingraham FD, Matson DD, Mc LRL (1952) Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. New Eng J Med 246:568-571
7. McKay L, Cidlowski J (2000) Corticosteroids. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum R, Holland JF, Frei E (eds) Holland-Frei Cancer Medicine. BC Decker Inc, Hamilton (ON)
8. Talar-Williams C, Sneller MC (1994) Complications of corticosteroid therapy. Eur Arch Oto-Rhino Laryngol 251:131-136 (Pubitemid 24185340)
9. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
10. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972
11. Millar BM, Bezjak A, Tsao M, Sturdza A, Laperriere N (2004) Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases. Clin Oncol (R Coll Radiol) 16:339-344 (Pubitemid 38967254)
12. Sandercock PA, Soane T (2011) Corticosteroids for acute ischaemic stroke. Cochrane Database Syst Rev
13. Andersen C, Astrup J, Gyldensted C (1994) Quantitation of peritumoural oedema and the effect of steroids using NMRrelaxation time imaging and blood-brain barrier analysis. Acta Neurochir Suppl 60:413-415
14. Kaal EC, Vecht CJ (2004) The management of brain edema in brain tumors. Curr Opin Oncol 16:593-600 (Pubitemid 39482980)
15. Stamatovic SM, Keep RF, Andjelkovic AV (2008) Brain endothelial cell-cell junctions: how to ''open'' the blood brain barrier. Curr Neuropharmacol 6:179-192
16. Wolburg H, Lippoldt A (2002) Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38:323-337 (Pubitemid 36398254)
17. Papadopoulos MC, Saadoun S, Woodrow CJ, Davies DC, Costa- Martins P, Moss RF, Krishna S, Bell BA (2001) Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathol Appl Neurobiol 27:384-395 (Pubitemid 32990079)
18. Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H, Wolburg H (2000) Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 100:323-331 (Pubitemid 30456160)
19. Saadoun S, Papadopoulos MC, Davies DC, Krishna S, Bell BA (2002) Aquaporin-4 expression is increased in oedematous human brain tumours. J Neurol Neurosurg Psychiatry 72:262-265
20. Machein MR, Plate KH (2000) VEGF in brain tumors. J Neuro-Oncol 50:109-120 (Pubitemid 32166295)
21. Machein MR, Kullmer J, Fiebich BL, Plate KH, Warnke PC (1999) Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 44:732-740 discussion 740-731
22. Peak SJ, Levin VA (2010) Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res 2:97-104
23. Roberts WG, Palade GE (1997) Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57:765-772 (Pubitemid 27085664)
24. Black KL, Hoff JT, McGillicuddy JE, Gebarski SS (1986) Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans. Ann Neurol 19:592-595 (Pubitemid 16085195)
25. Nathoo N, Barnett GH, Golubic M (2004) The eicosanoid cascade: possible role in gliomas and meningiomas. J Clin Pathol 57:6-13 (Pubitemid 38091302)
26. Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, Edwards NA, Oldfield EH (1996) Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 98:1400-1408 (Pubitemid 26322065)
27. Criscuolo GR, Balledux JP (1996) Clinical neurosciences in the decade of the brain: hypotheses in neuro-oncology. VEG/PF acts upon the actin cytoskeleton and is inhibited by dexamethasone: relevance to tumor angiogenesis and vasogenic edema. Yale J Biol Med 69:337-355 (Pubitemid 126687223)
28. Ohnishi T, Sher PB, Posner JB, Shapiro WR (1990) Capillary permeability factor secreted by malignant brain tumor. Role in peritumoral brain edema and possible mechanism for anti-edema effect of glucocorticoids. J Neurosurg 72:245-251 (Pubitemid 20087713)
29. Bruce JN, Criscuolo GR, Merrill MJ, Moquin RR, Blacklock JB, Oldfield EH (1987) Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. J Neurosurg 67:880-884 (Pubitemid 18005534)
30. Kim H, Lee JM, Park JS, Jo SA, Kim YO, Kim CW, Jo I (2008) Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of bloodbrain barrier. Biochem Biophys Res Commun 372:243-248
31. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745
32. Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, Preston JK (2000) Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 93:634-639 (Pubitemid 32799298)
33. Leenders KL, Beaney RP, Brooks DJ, Lammertsma AA, Heather JD, McKenzie CG (1985) Dexamethasone treatment of brain tumor patients: effects on regional cerebral blood flow, blood volume, and oxygen utilization. Neurology 35:1610-1616 (Pubitemid 16248671)
34. Behrens PF, Ostertag CB, Warnke PC (1998) Regional cerebral blood flow in peritumoral brain edema during dexamethasone treatment: a xenon-enhanced computed tomographic study. Neurosurgery 43:235-241 (Pubitemid 28354633)
35. Sturdza A, Millar BA, Bana N, Laperriere N, Pond G, Wong RK, Bezjak A (2008) The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 16:1041-1048
36. Pilkey J, Daeninck PJ (2008) A retrospective analysis of dexamethasone use on a Canadian palliative care unit. Prog Palliat Care 16:63-68
37. Hardy JR, Rees E, Ling J, Burman R, Feuer D, Broadley K, Stone P (2001) A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med 15:3-8 (Pubitemid 32103352)
38. McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, Olivi A, Quinones-Hinojosa A (2008) Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 63:286-291
39. The Boston Collaborative Drug Surveillance Program (1972) Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 13: 694-698
40. Adachi JD, Papaioannou A (2001) Corticosteroid-induced osteoporosis: detection and management. Drug Safety 24:607-624 (Pubitemid 32656074)
41. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 44:675-680 (Pubitemid 24129996)
42. Stanbury RM, Graham EM (1998) Systemic corticosteroid therapy- side effects and their management. Br J Ophthalmol 82:704-708 (Pubitemid 28306665)
43. Benvenuti S, Brandi ML (2000) Corticosteroid-induced osteoporosis: pathogenesis and prevention. Clin Exp Rheumatol 18:S64-S66 (Pubitemid 30655862)
44. Manson SC, Brown RE, Cerulli A, Vidaurre CF (2009) The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 103:975-994
45. Huizenga NA, Koper JW, de Lange P, Pols HA, Stolk RP, Grobbee DE, de Jong FH, Lamberts SW (1998) Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab 83:47-54 (Pubitemid 28498309)
46. Huizenga NA, Koper JW, De Lange P, Pols HA, Stolk RP, Burger H, Grobbee DE, Brinkmann AO, De Jong FH, Lamberts SW (1998) A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 83:144-151 (Pubitemid 28498326)
47. van Rossum EF, Lamberts SW (2004) Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 59:333-357
48. Van Rossum EFC, Koper JW, Van Den Beld AW, Uitterlinden AG, Arp P, Ester W, Janssen JAMJL, Brinkmann AO, De Jong FH, Grobbee DE, Pols HAP, Lamberts SWJ (2003) Identification of the Bc/I polymorphism in the glucocorticoid receptor gene: Association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol 59:585-592 (Pubitemid 37357618)
49. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO, Medical Research Council Childhood Leukaemia Working (2005) Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129:734-745 (Pubitemid 40904523)
50. Hanks GW, Trueman T, Twycross RG (1983) Corticosteroids in terminal cancer - a prospective analysis of current practice. Postgrad Med J 59:702-706 (Pubitemid 14235540)
51. Aulakh R, Singh S (2008) Strategies for minimizing corticosteroid toxicity: a review. Indian J Pediatr 75:1067-1073
52. Pereira RMR, Freire JC (2011) Glucocorticoid-induced myopathy. Joint Bone Spine 78:41-44
53. Kirkham SR (1988) The palliation of cerebral tumours with highdose dexamethasone: a review. Palliat Med 2:27-33
54. Nesher G, Rubinow A, Sonnenblick M (1997) Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Clin Exp Rheumatol 15:303-306 (Pubitemid 27261951)
55. Marantidou A, Levy C, Duquesne E, Ursu R, Bailon O, Coman I, Belin C, Carpentier AF (2010) Steroid requirements during radiotherapy for malignant gliomas. J Neuro-Oncol 100:89-94
56. Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10:322-328 (Pubitemid 36056287)
57. Weissman DE, Janjan NA, Erickson B, Wilson FJ, Greenberg M, Ritch PS, Anderson T, Hansen RM, Chitambar CR, Lawton CA et al (1991) Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. J Neuro-Oncol 11:235-239
58. Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Kalkanis SN (2010) The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:103-114
59. Frauman AG (1996) An overview of the adverse reactions to adrenal corticosteroids. Adverse Drug React Toxicol Rev 15:203-206 (Pubitemid 27156338)
60. Gannon C, McNamara P (2002) A retrospective observation of corticosteroid use at the end of life in a hospice. J Pain Symptom Manage 24:328-335
61. Gannon C (2001) The prescription of steroids in the terminal phase. Palliat Med 15:522
62. Mercadante S, Villari P, Intravaia G (2007) Withdrawal acute psychosis after corticosteroid discontinuation. J Pain Symptom Manage 34:118-119 (Pubitemid 47088910)
63. Vredenburgh J, Cloughesy TF, Samant M, Fang L, Das A, Friedman H (2009) Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the brain study. Neuro-Oncology 11:1329-1334
64. Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131-1138
65. Shapiro WR, Mechtler L, Cher L, Wheeler H, Hines V, Milsted R, O'Connor PC, Ryan RP, Recht L (2009) A randomized, double-blind study comparing corticorelin acetate with dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptoms of peritumoral brain edema. J Clin Oncol 27; (abstract)
66. PN KesariS, Vick N (2003) Corticosteroids in neuro-oncology. In: Schiff D, Kesari S, Wen PY (eds) Cancer neurology in clinical practice. Humana Press, Totowa, pp 47-56
67. Chamberlin P, Meyer WJ 3rd (1981) Management of pituitaryadrenal suppression secondary to corticosteroid therapy. Pediatrics 67:245-251 (Pubitemid 11184028)
68. Pezner RD, Lipsett JA (1982) Peptic ulcer disease and other complications in patients receiving dexamethasone palliation for brain metastasis. West J Med 137:375-378 (Pubitemid 13173451)
69. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM (1997) Steroid myopathy in cancer patients. Neurology 48:1234-1238 (Pubitemid 27240540)